Stock Analysts’ Updated EPS Estimates for August 5th (AG, AKT, AZN, CM, EVGO, NA, OBX, PODD, RAPP, VNP)

Stock Analysts’ updated eps estimates for Wednesday, August 5th:

AG.L (LON:AG) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a GBX 800 target price on the stock.

Akita Drilling (TSE:AKT) was downgraded by analysts at ATB Cormark Capital Markets from an outperform rating to a sector perform rating. ATB Cormark Capital Markets currently has C$4.25 price target on the stock, down from their previous price target of C$5.00.

AstraZeneca (LON:AZN) had its sell rating reissued by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a £115 target price on the stock.

Canadian Imperial Bank of Commerce (TSE:CM) (NYSE:CM) was downgraded by analysts at Desjardins from a buy rating to a hold rating. They currently have C$173.00 price target on the stock, up from their previous price target of C$160.00.

EVgo (NASDAQ:EVGO) had its hold rating reaffirmed by analysts at Needham & Company LLC.

National Bank of Canada (TSE:NA) was downgraded by analysts at Desjardins from a buy rating to a hold rating. They currently have C$238.00 target price on the stock, up from their previous target price of C$217.00.

Piper Sandler began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX). They issued an overweight rating and a $42.00 target price on the stock.

Insulet (NASDAQ:PODD) was downgraded by analysts at Oppenheimer Holdings, Inc. from an outperform rating to a market perform rating.

Rapport Therapeutics (NASDAQ:RAPP) had its buy rating reaffirmed by analysts at BTIG Research. BTIG Research currently has a $65.00 target price on the stock.

5N Plus (TSE:VNP) was upgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a strong-buy rating. They currently have C$45.00 target price on the stock.

Zebra Technologies (NASDAQ:ZBRA) had its outperform rating reaffirmed by analysts at BNP Paribas Exane. The firm currently has a $455.00 target price on the stock, up from their previous target price of $370.00.